El cinacalcet
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-CINACALCET |
|---|---|
| Tipo | Fármaco |
| Aliaces | MimparaSensibilizaciónЦинакалцет |
| Situación | reviewed 2026-07-11 | pending_clinical_signoff |
| Enfermedades | DIS-PARATHYROID-CARCINOMA |
| Fuentes | SRC-NCCN-THYROID-2025 |
Datos sobre drogas
| Clase | Calcimimético (agonista alostérico receptor de la sensibilidad al calcio) |
|---|---|
| Mecanismo | Alostéricamente aumenta la sensibilidad del receptor de calcio paratiroideo (CaSR) al calcio extracelular, suprimiendo la secreción de PTH y reduciendo el calcio sérico. Actúa sobre la consecuencia bioquímica de la enfermedad (hipercalcemia impulsada por PTH) en lugar del propio tumor, sin efecto directo antitumor / citotóxico. |
| Dosificación típica | Initiate 30 mg PO BID. Titrate no more frequently than every 2-4 weeks through sequential doses of 30 mg BID → 60 mg BID → 90 mg BID → 90 mg TID → 90 mg QID (maximum labeled dose) to normalize serum calcium. Take with food (improves bioavailability). Check serum calcium within 1 week of initiation or any dose change. FDA-approved specifically for hypercalcemia of parathyroid carcinoma (also approved for secondary hyperparathyroidism in dialysis-dependent CKD and severe hypercalcemia in primary hyperparathyroidism when parathyroidectomy is not appropriate). |
| Ucrania registrada | Falso |
| NSZU reembolsado | Falso |
| Ucrania verificada por última vez | 2026-07-11 |
Notas
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content, not published/verified clinical advice). Cinacalcet is the only FDA-approved medical therapy specifically labeled for hypercalcemia of parathyroid carcinoma. It has no cytostatic/cytotoxic effect on the tumor — it controls the biochemical consequence (PTH-driven hypercalcemia) in unresectable, recurrent, or metastatic disease. Distinct from bisphosphonates (DRUG-ZOLEDRONATE) / denosumab (DRUG-DENOSUMAB) — already in the KB — which act on osteoclast-mediated bone turnover to prevent skeletal-related events from bone metastases rather than suppressing PTH secretion; the two mechanisms are complementary and may be used concurrently in refractory hypercalcemia, per the parent Disease entity's narrative (DIS-PARATHYROID-CARCINOMA).
Utilizado por
Enfermedad
DIS-PARATHYROID-CARCINOMA- Carcinoma paratiroideo
Esquema terapéutico
REG-CINACALCET-HYPERCALCEMIA- Cinacalcet para hipercalcemia de carcinoma paratiroideo